Payment overview · 2025
General Payments
$2,059.53
26 reported records · 9 companies
Healthcare provider profile · identity verified
Luis J. Forastieri, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CAGUAS, PR · NPI 1902808553
Verified facts
What the public records show
CMS Open Payments records show Luis J. Forastieri, M.D. received $2,059.53 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 87.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rytary by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,810.34 | 87.9% | 13 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $75.34 | 3.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.61 | 2.5% | 3 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $37.92 | 1.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.28 | 0.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.14 | 0.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.84 | 0.9% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.32 | 0.7% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.74 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $1,575.00 | 1 |
| Food and Beverage | $484.53 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $111.53 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.53 | 4 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $84.88 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $75.34 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $63.93 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $50.61 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $37.92 | 2 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | E.R. Squibb & Sons, L.L.C. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PBG PUERTO RICO LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
95 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 1631 | 332 |
| Memantine Hcl | Memantine Hcl | 1420 | 293 |
| Gabapentin | Gabapentin | 644 | 131 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 575 | 89 |
| Sertraline Hcl | Sertraline Hcl | 527 | 104 |
| Rivastigmine | Rivastigmine | 431 | 86 |
| Clonazepam | Clonazepam | 407 | 78 |
| Levetiracetam | Levetiracetam | 297 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 204 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 183 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 151 | 34 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 142 | 31 |
| Baclofen | Baclofen | 140 | 31 |
| Primidone | Primidone | 138 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 35 |
| Trazodone Hcl | Trazodone Hcl | 126 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 122 | 20 |
| Memantine Hcl Er | Memantine Hcl | 119 | 21 |
| Temazepam | Temazepam | 118 | 18 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 101 | 18 |
| Pregabalin | Pregabalin | 101 | 25 |
| Galantamine Er | Galantamine Hbr | 97 | 22 |
| Rytary | Carbidopa/Levodopa | 95 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 20 |
| Nabumetone | Nabumetone | 92 | 23 |
| Lamotrigine | Lamotrigine | 91 | 14 |
| Famotidine | Famotidine | 89 | 19 |
| Topiramate | Topiramate | 86 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 67 | 18 |
| Rasagiline Mesylate | Rasagiline Mesylate | 66 | 11 |
| Phenobarbital | Phenobarbital | 64 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 62 | 20 |
| Carbamazepine | Carbamazepine | 59 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 14 |
| Lorazepam | Lorazepam | 56 | 16 |
| Propranolol Hcl | Propranolol Hcl | 55 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 54 | 12 |
| Divalproex Sodium | Divalproex Sodium | 52 | 11 |
| Meloxicam | Meloxicam | 52 | 12 |
| Amantadine | Amantadine Hcl | 51 | 11 |
| Omeprazole | Omeprazole | 50 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Tegretol Xr | Carbamazepine | 44 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 43 | suppressed |
| Lacosamide | Lacosamide | 43 | suppressed |
| Entacapone | Entacapone | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Etodolac | Etodolac | 30 | suppressed |
| Neupro | Rotigotine | 30 | suppressed |
| Losartan Potassium | Losartan Potassium | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Phenytoin | Phenytoin | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 19 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 18 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Botox | Onabotulinumtoxina | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Keppra | Levetiracetam | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 14 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 13 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Depakote Sprinkle | Divalproex Sodium | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,059.53 · 26 records | ABBVIE INC. | BOTOX, CREXONT, EMGALITY, KESIMPTA, KISUNLA, NURTEC ODT, PURIFIED CORTROPHIN GEL, QULIPTA, UBRELVY, ULTOMIRIS, VYALEV, WAINUA, ZAVZPRET, ZEPOSIA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error